Idera Pharmaceuticals, Inc. today announced that it has regained global rights to IMO-2055, an agonist of Toll-like Receptor (TLR) 9, as part of an agreed-upon termination of its oncology collaboration with Merck KGaA, Darmstadt, Germany.

Luther T. Clark, MD, FACC, will discuss preclinical drug discovery and development at SUNY Downstate Medical Center, Thursday, December 1, 2011. Dr. Clark's presentation will take place at 12:00 noon in the Health Science Education Building, Lecture Hall 1 A, 395 Lenox Road, Brooklyn, New York 11203. ...

(SUNY Downstate Medical Center) Luther T. Clark, M.D., FACC, will discuss preclinical drug discovery and development at SUNY Downstate Medical Center, Thursday, Dec. 1, 2011. Dr. Clark's presentation will take place at 12 p.m. in the Health Science Education Building, Lecture Hall 1 A, 395 Lenox Road, Brooklyn, N.Y., 11203.

The pharmaceutical giant will pay a $321 million criminal fine and a $628 million civil settlement.

By Steven Reinberg HealthDay Reporter TUESDAY, Nov. 22 (HealthDay News) -- The U.S. Justice Department said Tuesday that the drug company Merck will pay $950 million to resolve investigations into its marketing of the blockbuster painkiller Vioxx, which was pulled from the market ...

Merck & Co. will pay $950 million and one of its units will plead guilty to a criminal charge to resolve a U.S. probe of its illegal marketing of the painkiller Vioxx.

(AP) -- The Department of Justice says Merck will pay $950 million to resolve investigations into its marketing of the painkiller Vioxx.

A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.

In 2010 an Australian law court found in favor a man who blamed the recalled drug for a heart attack he suffered. That ruling now seems to have been overturned in appeal; a win for Merck and its problem Vioxx product. Vioxx which was removed from the market in 2004 ...

The U.S. Food and Drug Administration (FDA) has approved Merck & Co.’s Juvisync diabetes drug, a combination pill for type 2 diabetes. Juvisync combines two Merck drugs already on the market, 1) glucose-lowering Januvia (Sitagliptin) medication and 2) cholesterol-lowering Zocor (Simvastatin).

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

Merck, known as MSD outside the United States and Canada, today said a federal court jury in New York found in its favor in the Secrest v. Merck case, rejecting the claim of a Florida woman who blamed her dental and jaw-related problems on her FOSAMAX use.